Bavencio becomes first treatment for rare skin cancer mMCC licensed for use in the UK

7 Nov 2017

The launch of avelumab marks a step-change in the way that mMCC can be treated.

Merck and Pfizer have announced the UK launch of Bavenio (avelumab) solution for infusion 20 mg/mL, as a monotherapy for the treatment of mMCC in adults. Avelumab is the first medicine to be licensed for this rare, aggressive type of skin cancer.

Bavencio becomes first treatment for rare skin cancer mMCC licensed for use in the UK

“The licensing of avelumuab in this disease is an advance for patients as it is well tolerated, and active,” commented Professor Ruth Plummer, Consultant Medical Oncologist at the Newcastle upon Tyne Hospitals NHS Foundation Trust. “Patients with mMCC are often elderly and find our standard chemotherapy hard going, needing dose reductions or breaks from treatment.”

The incidence of mMCC is so low that it is hard to be accurate; it is thought, however, that there are approximately 50 new cases of mMCC annually in the UK. However, data show that the incidence of MCC is rising possibly due to an ageing population or increased UV exposure. MCC exhibits aggressive clinical features, including frequent lymph node involvement and early metastases. Patients with mMCC have a very poor prognosis, with fewer than half of patients surviving more than one year and fewer than 20% surviving beyond 5 years.

While earlier-stage MCC can be generally managed with surgery and radiotherapy, treatment options for mMCC are severely limited. Until now, there have been no licensed medicines to treat mMCC in the UK. As such, the standard of care for patients with mMCC is to enrol in clinical trials.

The efficacy and safety of avelumab was demonstrated in the JAVELIN Merkel 200 trial, an international, multicentre, single-arm, open-label, Phase II study with two parts (still ongoing):

  • Part A15,16 included 88 patients with mMCC whose disease had progressed after at least one chemotherapy treatment. The objective response rate was 33%, with 11% of patients experiencing a complete response and 22% of patients experiencing a partial response. Responses were noted at the time of the first post-baseline tumour assessment (week 7) in 22 (76%) of 29 patients. At the time of analysis, tumour responses were durable, with 93% of responses lasting at least 6 months and 71% of responses lasting at least 12 months. The overall survival rate at 6 months was 69%.
  • Part B (still enrolling), at the time of the data cut-off (March 2017), included 39 patients with histologically confirmed mMCC who were treatment-naïve to systemic therapy in the metastatic setting. The objective response rate was 62%, with 14% of patients experiencing a complete response (CR) and 48% of patients experiencing a partial response (PR). 16 of 18 confirmed responses (88.9%) occurred approximately 6 weeks after treatment initiation.
  • Avelumab was well tolerated in line with the overall safety database. Most AEs related to treatment were low grade, including all infusion reactions.
  • “We’re really encouraged by the news that avelumab is now licensed for use in the UK,” commented Catherine Bouvier, CEO of the NET Patient Foundation. “Although rare, mMCC is an aggressive cancer with potentially worse outcomes than other types of skin cancer such as melanoma. An effective, well-tolerated treatment option will be welcomed with open arms by patients with mMCC and their families, so we hope that all stakeholders will work in a collaborative way to ensure that patients in the UK now have access to it as quickly as possible.”

    “Today is a significant milestone for the Alliance between Merck and Pfizer,” commented Dr Belinda Byrne, Medical Director at Merck, UK. “It demonstrates our commitment to working in partnership to develop new treatment options for patients with hard-to-treat cancers and we are looking forward to exploring future potential monotherapy indications and a diverse range of novel combinations with avelumab.”

    Read More

    Related tags

    Research & Development

    Related news

    Plasticell wins military contract to develop regenerative medicines for the battlefield

    Plasticell wins military contract to develop regenerative medicines for the battlefield

    4 Sep 2018

    Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

    Read more 
    New biopharmaceutical testing laboratory to open in Geneva

    New biopharmaceutical testing laboratory to open in Geneva

    28 Aug 2018

    SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

    Read more 
    Exosome isolation manufacturing and characterization

    Exosome isolation manufacturing and characterization

    13 Aug 2018

    New service to reliably and reproducibly isolate exosomes from almost any biofluid.

    Read more 
    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    8 Aug 2018

    Company moves away from manual processing in favour of automated, scalable platforms.

    Read more 
    A new era for migraine patients

    A new era for migraine patients

    6 Aug 2018

    EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

    Read more 
    WuXi STA and Antengene sign development and manufacturing agreement

    WuXi STA and Antengene sign development and manufacturing agreement

    24 Jul 2018

    WuXi STA chosen for its end-to-end CMC platform for new drug development.

    Read more 
    ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

    ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

    18 Jul 2018

    Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

    Read more 
    New screening company exploits the latest advances in microfluidics and 3D culture

    New screening company exploits the latest advances in microfluidics and 3D culture

    19 Jul 2018

    The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

    Read more 
    Natural lipid acts as potent anti-inflammatory

    Natural lipid acts as potent anti-inflammatory

    10 Jul 2018

    Scientists see therapeutic potential against bacteria, viruses.

    Read more 
    Plasticell leads gene therapy manufacturing consortium

    Plasticell leads gene therapy manufacturing consortium

    3 Jul 2018

    Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

    Read more